Elijah Owens, MD
Neurology · Florence, SCNPI 1417156886
Payments from drug & device makers
Across 251 payments — averaging $19.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$581
- Biogen$516
- Novartis$488
- SK Life Science, Inc.$344
- Sanofi$230
- Teva Pharmaceuticals USA, Inc.$207
- plus $3K from 33 others
What the payments were for
- Food & beverage$4,915100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 23 | $581 |
| Biogen | 25 | $516 |
| Novartis | 25 | $488 |
| SK Life Science, Inc. | 18 | $344 |
| Sanofi | 12 | $230 |
| Teva Pharmaceuticals USA, Inc. | 12 | $207 |
| Bristol Myers Squibb | 11 | $196 |
| Neurocrine Biosciences, Inc. | 7 | $181 |
| Amgen(2 entities) | 8 | $181 |
| Genentech USA, Inc. | 12 | $181 |
| AstraZeneca | 9 | $170 |
| Acadia Pharmaceuticals Inc | 8 | $162 |
| EMD Serono, Inc. | 7 | $124 |
| Argenx US, Inc. | 5 | $119 |
| Eisai Inc. | 6 | $117 |
| AbbVie | 7 | $109 |
| Johnson & Johnson | 5 | $106 |
| Sunovion Pharmaceuticals Inc. | 7 | $100 |
| Sumitomo Pharma America, Inc. | 4 | $94 |
| Lundbeck LLC | 4 | $85 |
| MDD US Operations, LLC | 5 | $77 |
| Lilly USA, LLC | 5 | $73 |
| Supernus Pharmaceuticals, Inc. | 4 | $69 |
| Corium, LLC | 3 | $62 |
| Mallinckrodt Enterprises LLC | 3 | $57 |
| Pfizer | 3 | $43 |
| Boston Scientific | 1 | $38 |
| Livanova USA, Inc. | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Medtronic | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Amylyx Pharmaceuticals, Inc. | 1 | $21 |
| Genentech, Inc. | 1 | $18 |
| Adamas Pharmaceuticals, Inc. | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Cala Health, Inc. | 1 | $13 |
| Grifols USA, LLC | 1 | $12 |
| CSL Behring | 1 | $11 |
How this compares
$4,927 in reported general payments places this provider in the 65th percentile of 270 neurology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 69 | $667,934 |
| CopaxoneGlatiramer Acetate | 23 | $169,493 |
| NuplazidPimavanserin Tartrate | 29 | $153,025 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 19 | $140,327 |
| AustedoDeutetrabenazine | 14 | $127,107 |
| BetaseronInterferon Beta-1b | 13 | $112,130 |
| Emgality PenGalcanezumab-Gnlm | 72 | $107,587 |
| Aimovig AutoinjectorErenumab-Aooe | 63 | $103,546 |
| Plegridy PenPeginterferon Beta-1a | 12 | $97,032 |
| IngrezzaValbenazine Tosylate | 12 | $74,615 |
| GocovriAmantadine Hcl | 18 | $65,976 |
| UbrelvyUbrogepant | 33 | $60,049 |
| Nurtec OdtRimegepant Sulfate | 17 | $41,952 |
| NayzilamMidazolam | 26 | $41,256 |
| GlatopaGlatiramer Acetate | 24 | $33,907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Copaxone, Austedo | $207 | $296,60037 claims |
| Acadia Pharmaceuticals IncNuplazid | $162 | $153,02529 claims |
| AbbVieUbrelvy, Qulipta | $109 | $79,59846 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $181 | $74,61512 claims |
| MDD US Operations, LLCGocovri | $77 | $65,97618 claims |
| PfizerNurtec Odt | $43 | $41,95217 claims |
| UCB, Inc.Nayzilam | $581 | $41,25626 claims |
| Eisai Inc.Fycompa | $117 | $26,70217 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $100 | $17,75112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 270 neurology providers in South Carolina.
Other neurology in Florence
- Christopher ZustFlorence$39K
- Robert HealyFlorence$24K
- Walter EvansFlorence$21K
- Mary HughesGreenville$6.3M
- William McElveenColumbia$3.7M
- Robert CarlileSummerville$2.3M
- Andrew KeeganCharleston$2.2M
- Paul MazzeoPort Royal$1.7M
- Vanessa HinsonCharleston$1.5M
- David SticklerNorth Charleston$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.